Comparison of a new enzymatic assay with a high-performance liquid chromatography/ultraviolet detection method for therapeutic drug monitoring of mycophenolic acid in adult liver transplant recipients

Liver Transplantation

Volumn 14, Issue 12, 2008, Pages 1745-1751

  Blanchet, Benoit ^a   Taieb, Fabrice ^a   Conti, Filomena ^a   Abbas, Halim ^a   Seydi, Idrissa ^a   Harcouet, Laura ^a   Dauphin, Alain ^a   Calmus, Yvon ^a   Tod, Michel ^a,b  

^a GH Cochin Saint Vincent de Paul ^*  (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THIOPENTAL; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; ENZYMATIC ASSAY; FEMALE; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS; ADULT; BLOOD; COMPARATIVE STUDY; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; EVALUATION; GRAFT REJECTION; LIVER; METABOLISM; METHODOLOGY; MIDDLE AGED; STANDARD; ULTRAVIOLET RADIATION;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; ULTRAVIOLET RAYS;

EID: 58249086158     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21607     Document Type: Article

References (29)

1. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005; 11:750-759.
2. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7: 442-450.
3. Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004;18:463-472.
4. Dumortier J, Gagnieu MC, Salandre J, Guillaud O, Guillem P, Adham M, Boillot O. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study. Liver Transpl 2006;12:1342-1346.
5. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46:13-58.
6. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized doubleblind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261-266.
7. Hale MD, Nicholls AJ, Bullingham RE, Hene R, Hoitsma A, Squifflet JP, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64:672-683.
8. Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007;7:2496-2503.
9. Pisupati J, Jain A, Burckart G, Hamad I, Zuckerman S, Fung J, Venkataramanan R. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005;45:34-41.
10. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28:145-154.
11. Hosotsubo H, Takahara S, Imamura R, Kyakuno M, Tanaka T, Yazawa K, et al. Analytic validation of the enzyme multiplied immunoassay technique for the determination of mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatographic assay. Ther Drug Monit 2001;23:669-674.
12. Schutz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L, Tonshoff B, et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998; 30:1185-1187.
13. Westley IS, Ray JE, Morris RG. CEDIA mycophenolic acid assay compared with HPLC-UV in specimens from transplant recipients. Ther Drug Monit 2006;28:632-636.
14. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002;48:517-525.
15. Premaud A, Rousseau A, Le Meur Y, Lachatre G, Marquet P. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 2004; 26:609-619.
16. Beal JL, Jones CE, Taylor PJ, Tett SE. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a highperformance liquid chromatography assay. Ther Drug Monit 1998;20:685-690.
17. Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Oellerich M, Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 2000;46:365-372.
18. Marquet P, Premaud A, Sauvage F, Jaqz-Aigrain E, Tiberi M, Domke I. Evaluation of a new enzymatic assay for the determination of mycophenolate in plasma by comparison with LC-MS/MS in different graft types and combinations of immunosuppressants. Abstract presented at: World Transplant Congress; 2006; Boston, MA.
19. Dorn AR, Tsai J, Mountain L, Phillips M, Rugaber J, Zhou C, et al. Assessment of total and free mycophenolic acid in transplant patient plasma by enzyme receptor assay [abstract]. Ther Drug Monit 2005;27(suppl):216.
20. Hosotsubo H, Takahara S, Kokado Y, Permpongkosol S, Wang JD, Tanaka T, et al. Rapid and simultaneous determination of mycophenolic acid and its glucuronide conjugate in human plasma by ion-pair reversed-phase high-performance liquid chromatography using isocratic elution. J Chromatogr B Biomed Sci Appl 2001;753:315-320.
21. Passing H, Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. J Clin Chem Clin Biochem 1983;21:709-720.
22. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
23. Hao C, Erzheng C, Anwei M, Zhicheng Y, Baiyong S, Xiaxing D, et al. Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. Liver Transpl 2007;13: 1684-1693.
24. Zicheng Y, Weixia Z, Hao C, Hongzhuan C. Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult patients undergoing liver transplant. Ther Drug Monit 2007; 29:207-214.
25. Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004;10:492-502.
26. Gonzalez-Roncero FM, Govantes MA, Chaves VC, Palomo PP, Serra MB. Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients. Transplant Proc 2007;39:2176-2178.
27. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: ontreatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008;14:53-58.
28. Franchetti P, Grifantini M. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr Med Chem 1999;6:599-614.
29. Morello J, Rodriguez-Novoa S, Cantillano AL, Gonzalez-Pardo G, Jimenez I, Soriano V. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Ther Drug Monit 2007;29:802-806.